A single-center experience of central nervous system tumors in children under three years old

被引:0
|
作者
Wang, Junhua [1 ,2 ]
Wang, Chuanwei [3 ]
Huang, Zhimin [1 ,2 ]
Zhang, Zhihua [1 ,2 ]
Zhang, Yuqi [1 ,2 ]
机构
[1] Tsinghua Univ, Tsinghua Univ Hosp Integrated Tradit Chinese & Wes, Yuquan Hosp, Dept Neurosurg, Beijing, Peoples R China
[2] Tsinghua Univ, Sch Clin Med, Beijing, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Neurosurg, Jinan, Shandong, Peoples R China
来源
FRONTIERS IN PEDIATRICS | 2024年 / 12卷
关键词
central nervous system; pediatrics; child; tumor; neurosurgery; chemotherapy; HIGH-DOSE CHEMOTHERAPY; STEM-CELL RESCUE; HEAD-START-I; BRAIN-TUMORS; MEDULLOBLASTOMA; AGE; SURVIVAL; OUTCOMES; RISK; RADIOTHERAPY;
D O I
10.3389/fped.2024.1441016
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose This study aims to summarize the characteristics of children under three years old (<= 3 years) with central nervous system (CNS) tumors and to investigate the factors that influence their overall survival (OS) time.Methods We treated 171 pediatric patients (<= 3 years) with CNS tumors at Yuquan Hospital of Tsinghua University from January 2016 to June 2023. Of these, 162 cases were successfully followed up. Kaplan-Meier survival analysis and Cox regression were utilized to evaluate factors potentially influencing OS of malignancies.Results There was a male predominance among the patients. The three most common tumors were embryonal tumors, gliomas, and craniopharyngiomas. Gross total resection (GTR) was achieved in select cases. Patients with high-grade malignancies were advised to undergo chemotherapy and/or radiotherapy after surgery. Optic gliomas and diffuse midline gliomas were partially resected and treated with adjuvant treatments. The median survival time of low-grade malignant tumors was 41.5 months, while that of high-grade malignant tumors was 15 months. Kaplan-Meier survival analysis identified the factors potentially influencing OS of malignancies: extent of resection, CNS WHO grade, grade of malignancies, and Ki-67 labeling index (Ki-67 LI). Subsequent multivariate analysis highlighted the interactive factor (extent of resection x CNS WHO grade) along with Ki-67 LI, as the most significant variables. Factors such as sex, age, tumor location, and onset-to-treatment time appeared not to affect OS.Conclusions GTR remains the cornerstone of treatment for children (<= 3 years) with CNS tumors, except for optic glioma, diffuse midline glioma, and germinoma. The interactive factor (extent of resection x CNS WHO grade) and Ki-67 LI are the most significant factors affecting OS. The implementation of preoperative neoadjuvant chemotherapy and early postoperative chemotherapy may enhance prognosis.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] CENTRAL NERVOUS SYSTEM TUMORS IN CHILDREN LESS THAN THREE YEARS OLD: A SINGLE CENTER EXPERIENCE
    Linares, Adriana
    Bolanos, Carlos
    Jaramillo, Lina
    Restrepo, Fabio
    Paula Aristizabal, Maria
    Martinez, Carlos
    Sarmiento, Isabel
    Murcia, Susana
    Cortes, Mauricio
    Castano, Silverio
    Izquierdo, Alvaro
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 836 - 836
  • [2] Clinical factors, management, and outcomes of children under 3 years old with central nervous system tumors: single-center experience
    Eker, Nursah
    Tokuc, Gulnur
    Sarisaltik, Alican
    Dagcinar, Adnan
    Gul, Dilek
    Atasoy, Beste Melek
    Yilmaz, Baris
    Tas, Burcu Tufan
    CHILDS NERVOUS SYSTEM, 2024, 40 (08) : 2311 - 2320
  • [3] Clinical Factors, Management, and Outcomes of Patients Under 18 Years Old With Central Nervous System Tumors: Single-center Experience in Peru
    Morales, Claudia Pascual
    Ponce, Liliana Vasquez
    Briceno, Jose Hernandez
    Lopez, Esmeralda Leon
    Guevara, Julio Guevara
    Vargas, Josue Jimenez
    Coronado, Rosdali Diaz
    Flores, Jose D.
    Ayala, Manuel Lazon
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2023, 45 (03) : E345 - E349
  • [4] Presentation and symptom interval in children with central nervous system tumors. A single-center experience
    Stocco, Chiara
    Pilotto, Chiara
    Passone, Eva
    Nocerino, Agostino
    Tosolini, Raffaello
    Pusiol, Anna
    Cogo, Paola
    CHILDS NERVOUS SYSTEM, 2017, 33 (12) : 2109 - 2116
  • [5] Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience
    Kirkman, Matthew A.
    Hayward, Richard
    Phipps, Kim
    Aquilina, Kristian
    CHILDS NERVOUS SYSTEM, 2018, 34 (11) : 2259 - 2267
  • [6] Presentation and symptom interval in children with central nervous system tumors. A single-center experience
    Chiara Stocco
    Chiara Pilotto
    Eva Passone
    Agostino Nocerino
    Raffaello Tosolini
    Anna Pusiol
    Paola Cogo
    Child's Nervous System, 2017, 33 : 2109 - 2116
  • [7] Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience
    Matthew A. Kirkman
    Richard Hayward
    Kim Phipps
    Kristian Aquilina
    Child's Nervous System, 2018, 34 : 2259 - 2267
  • [8] Nimotuzumab therapy in the treatment of pediatric central nervous system tumors: single-center experience
    Susam-Sen, Hilal
    Varan, Ali
    Bajin, Inci
    Gocmen, Rahsan
    Aydin, Burca
    Yalcin, Bilgehan
    Kurucu, Nilgun
    Kutluk, Tezer
    Bayhan, Turhan
    Akyuz, Canan
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2021, 394 (08) : 1769 - 1777
  • [9] Pediatric Central Nervous System Tumors: A Single-center Experience From 1989 to 2009
    Pinho, Ricardo Silva
    Andreoni, Solange
    Silva, Nasjla Saba
    Cappellano, Andrea Maria
    Masruha, Marcelo Rodrigues
    Cavalheiro, Sergio
    Pereira Vilanova, Luiz Celso
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (08) : 605 - 609
  • [10] The use of bevacizumab in primary malignant tumors of the central nervous system: A single-center experience
    Pehlivan, Metin
    Ekenel, Meltem
    MEDICINE, 2023, 102 (30) : E34286